Zhongsheng Ruichuang

Zhongsheng Ruichuang is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative vaccines and antiviral therapeutics. Established as a high-tech subsidiary of the China National Biotec Group (CNBG) under Sinopharm, the company focuses on addressing major public health threats and infectious diseases. Its core technology includes the BC02 novel adjuvant platform and recombinant protein expression systems. The company's pipeline features a prominent bivalent Norovirus vaccine currently in clinical trials, alongside several COVID-19 treatments including 3CL protease inhibitors and monoclonal antibodies. Zhongsheng Ruichuang aims to bridge the gap between basic research and industrial-scale production for next-generation biological products.